Eaton Vance Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Eaton Vance Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$698K	Hold	10,000	–	–	﹤0.01%	1292
2022 Q2	$671K	Sell	10,000 -20,637	-67%	-$1.31M	﹤0.01%	1323
2022 Q1	$2.52M	Buy	30,637 +20,451	+201%	+$2.09M	﹤0.01%	1108
2021 Q4	$1.49M	Hold	10,186	–	–	﹤0.01%	1093
2021 Q3	$1.77M	Buy	10,186 +184	+2%	+$29.6K	﹤0.01%	961
2021 Q2	$1.62M	Sell	10,002 -450	-4%	-$72.3K	﹤0.01%	1057
2021 Q1	$1.79M	Buy	10,452 +451	+5%	+$89.3K	﹤0.01%	1004
2020 Q4	$2.2M	Buy	+10,001	New	+$2.16M	﹤0.01%	906
2020 Q3	–	Sell	-33,361	Closed	-$3.81M	–	1344
2020 Q2	$3.81M	Hold	33,361	–	–	0.01%	663
2020 Q1	$2.56M	Sell	33,361 -26,925	-45%	-$2.41M	0.01%	702
2019 Q4	$7.76M	Buy	+60,286	New	+$5.81M	0.02%	509

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Eaton Vance Management's MRTX Position: Q3 2022 in Review

Eaton Vance Management held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q3 2022 at 10,000 shares worth $698K. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

Eaton Vance Management first reported a position in MRTX in Q4 2019 and has held it in 11 quarters since. The position peaked at $7.76M in Q4 2019. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Eaton Vance Management held 10,000 shares of Mirati Therapeutics, Inc. Common Stock worth $698K as of Q3 2022.
Eaton Vance Management left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1292 holding.
Eaton Vance Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and has held it in 11 quarters since.
Eaton Vance Management's Mirati Therapeutics, Inc. Common Stock position peaked at $7.76M in Q4 2019.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.